BioMarin (BMRN) Says Data from Phase 1/2 '190 Study Shows Stabilization of Disease
- Wall Street rallies, snaps longest weekly losing streak in decades
- 'Always Bet on Michael': Dell (DELL) Stock Soars After Crushing Estimates, Analysts Say Results are Impressive
- Credit Suisse Says Tesla (TSLA) Stock Offers an Attractive Entry Point, Sees Nearly 60% Upside From Here
- Citi Downgrades US Equities to Neutral on Recession Risk
- Elon Musk Says Recession Could Last 12 to 18 Months, But 'Actually a Good Thing'
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced interim results from its Phase 1/2 pivotal study for BMN 190 or cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1), to treat of patients with late infantile CLN2 disease, a form of Batten disease. Interim data indicates that in all nine of the BMN 190 patients who have been followed for at least six months and up to 15 months, the treatment appears to show stabilization of the disease compared to the natural history based on a standardized measure of motor and language function.
The primary end point of the study is a standardized mobility and language score using a CLN2-specific rating scale. The scale separately measures performance of mobility and language with normal function in each being a score of three and no function being a score of zero. The highest score possible is six.
According to data from a natural history study of the disease, patients generally lose one point every six months and generally lose most language and mobility functioning over a two to four year period in this rapidly progressive disease. In the nine BMN 190 patients treated for more than six months and up to 15 months, six patients showed no net change in their CLN2 rating scale score, while the other three showed a decline of one point.
In addition, seven of the nine patients in the BMN 190 study for more than six months were matched to between one and 12 individuals from the natural history data set according to baseline age and disease severity. (For two of the BMN 190 patients, there is no matched patient in the natural history database based on age and disease severity.) All seven BMN 190 patients with six months of treatment and at least one control match had better walk/talk scores as of their last evaluation than their natural history counterparts.
Additional detailed information on the interim preliminary results from the nine patients who have been on BMN 190 for more than six months and their matched natural history counterparts can be found athttp://www.bmrn.com/pdf/JPMPresentation011215.pdf.
"This trial represents the essence of BioMarin's commitment to patients with fatal rare diseases and no treatment options. This initial look at the data is encouraging, and this therapy may make a meaningful difference for children with this form of Batten disease. We look forward to working with the regulatory authorities to determine if this single study will support regulatory approval as quickly as possible," said Jean-Jacques Bienaimé, Chief Executive Officer.
There is no approved treatment that can prevent, stop, or reverse CLN2 disorder. Palliative care—to reduce seizures—and physical rehabilitative care—to help children retain muscle function for as long as possible—are currently the available treatment options for patients with this rare disease.
"This interim data represents an important step on a journey to develop a treatment for CLN2 disorder that may be able to slow the course of this fatal disease," said Angela Schulz, M.D. Ph.D., Department of Paediatrics, University Medical Center Hamburg-Eppendorf. "We appreciate the commitment of the children and their families who are participating in this study."
"We welcome BioMarin's update on nine of the 24 patients participating in this clinical trial and appreciate the efforts they are making in developing a treatment for this deadly ultra-rare disease," said Andrea West, Chief Executive, Batten Disease Family Association.
"We are pleased about the progress that BioMarin is making in developing a treatment for CLN2 disorder," said Margie Frazier, Ph.D., Executive Director, Batten Disease Support and Research Association. "This is a notable moment, which holds promise for the children and families who are affected by this disease."
The Phase 1/2 pivotal study is an open-label, dose-escalation study in patients with late infantile CLN2 disease, a form of Batten disease. The primary objectives are to evaluate the safety and tolerability of BMN 190 or cerliponase alfa and to evaluate effectiveness using a CLN2 disorder-specific rating scale score in comparison with natural history data after 48 weeks of treatment. Secondary objectives are to evaluate the impact of treatment on brain atrophy in comparison with CLN2 natural history after 48 weeks of treatment and to characterize pharmacokinetics and immunogenicity. The study enrolled 24 subjects at five clinical sites for a planned treatment duration of 48 weeks. Complete results are expected in Q4 2015.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpringWorks (SWTX) Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting (earlier)
- Immersion (IMMR) Files Complaint Against Meta Platforms / Facebook With U.S. District Court for the Western District of Texas
- Purple Biotech Ltd. (PPBT) Reports Interim Phase 1 Data for NT219 Showing Encouraging Safety & Efficacy
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Hot FDA News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!